omodenbamab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
omodenbamab

GtoPdb Ligand ID: 13379

Synonyms: 514G3

Compound class: Antibody

Comment: Omodenbamab is a human IgG3 monoclonal antibody that targets the cell wall component Staphylococcus Protein A (SpA) of Staphylococcus aureus [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

No information available.

No information available.

Summary of Clinical Use
Omodenbamab received US FDA Fast Track designation for the treatment of S. aureus infections and is under clinical devlopment by XBiotech. A Phase 1/2 clinical trial to evaluate the safety and efficacy of omodenbamab in patients with bacteremia caused by S. aureus was completed in 2017 (NCT02357966). Results presented at IDWeek 2016, reported that omodenbamab was well tolerated and generated few severe adverse events [1]. As of May 2024, this mAb remains as part of XBiotech's development pipeline (access their pipeline webpage here).

Summary of Clinical Use

Omodenbamab received US FDA Fast Track designation for the treatment of S. aureus infections and is under clinical devlopment by XBiotech. A Phase 1/2 clinical trial to evaluate the safety and efficacy of omodenbamab in patients with bacteremia caused by S. aureus was completed in 2017 (NCT02357966). Results presented at IDWeek 2016, reported that omodenbamab was well tolerated and generated few severe adverse events [1].
As of May 2024, this mAb remains as part of XBiotech's development pipeline (access their pipeline webpage here).

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT02357966	A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus	Phase 1/Phase 2 Interventional	XBiotech, Inc.